These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 35199172

  • 1. Current management of giant-cell tumor of bone in the denosumab era.
    Nagano A, Urakawa H, Tanaka K, Ozaki T.
    Jpn J Clin Oncol; 2022 May 05; 52(5):411-416. PubMed ID: 35199172
    [Abstract] [Full Text] [Related]

  • 2. Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review.
    Tsukamoto S, Tanaka Y, Mavrogenis AF, Kido A, Kawaguchi M, Errani C.
    Clin Orthop Relat Res; 2020 May 05; 478(5):1076-1085. PubMed ID: 31794487
    [Abstract] [Full Text] [Related]

  • 3. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
    Müller DA, Beltrami G, Scoccianti G, Campanacci DA, Franchi A, Capanna R.
    World J Surg Oncol; 2016 Nov 04; 14(1):281. PubMed ID: 27809843
    [Abstract] [Full Text] [Related]

  • 4. Giant cell tumour of bone in the denosumab era.
    van der Heijden L, Dijkstra PDS, Blay JY, Gelderblom H.
    Eur J Cancer; 2017 May 04; 77():75-83. PubMed ID: 28365529
    [Abstract] [Full Text] [Related]

  • 5. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
    Zhang RZ, Ma TX, Qi DW, Zhao M, Hu T, Zhang GC.
    Orthop Surg; 2019 Dec 04; 11(6):1101-1108. PubMed ID: 31762217
    [Abstract] [Full Text] [Related]

  • 6. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis.
    Reddy K, Ramirez L, Kukreja K, Venkatramani R.
    J Pediatr Hematol Oncol; 2021 Mar 01; 43(2):e215-e218. PubMed ID: 31714440
    [Abstract] [Full Text] [Related]

  • 7. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
    Takeuchi A, Tsuchiya H, Ishii T, Nishida Y, Abe S, Matsumine A, Kawai A, Yoshimura K, Ueda T.
    BMC Musculoskelet Disord; 2016 Jul 22; 17():306. PubMed ID: 27448567
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage.
    Errani C, Tsukamoto S, Leone G, Righi A, Akahane M, Tanaka Y, Donati DM.
    J Bone Joint Surg Am; 2018 Mar 21; 100(6):496-504. PubMed ID: 29557866
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone.
    Lipplaa A, Dijkstra S, Gelderblom H.
    Curr Opin Oncol; 2019 Jul 21; 31(4):329-335. PubMed ID: 30844887
    [Abstract] [Full Text] [Related]

  • 15. Preoperative Denosumab Therapy Against Giant Cell Tumor of Bone is Associated with an Increased Risk of Local Recurrence After Curettage Surgery.
    Asano N, Saito M, Kobayashi E, Morii T, Kikuta K, Watanabe I, Anazawa U, Takeuchi K, Suzuki Y, Susa M, Nishimoto K, Ishii R, Miyazaki N, Mrioka H, Kawai A, Horiuchi K, Nakayama R.
    Ann Surg Oncol; 2022 Jun 21; 29(6):3992-4000. PubMed ID: 35175454
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
    Perrin DL, Visgauss JD, Wilson DA, Griffin AM, Abdul Razak AR, Ferguson PC, Wunder JS.
    Bone Joint J; 2021 Jan 21; 103-B(1):184-191. PubMed ID: 33380180
    [Abstract] [Full Text] [Related]

  • 18. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
    Scoccianti G, Totti F, Scorianz M, Baldi G, Roselli G, Beltrami G, Franchi A, Capanna R, Campanacci DA.
    Clin Orthop Relat Res; 2018 Sep 21; 476(9):1783-1790. PubMed ID: 30778015
    [Abstract] [Full Text] [Related]

  • 19. Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study.
    Urakawa H, Yonemoto T, Matsumoto S, Takagi T, Asanuma K, Watanuki M, Takemoto A, Naka N, Matsumoto Y, Kawai A, Kunisada T, Kubo T, Emori M, Hiraga H, Hatano H, Tsukushi S, Nishida Y, Akisue T, Morii T, Takahashi M, Nagano A, Yoshikawa H, Sato K, Kawano M, Hiraoka K, Tanaka K, Iwamoto Y, Ozaki T.
    World J Surg Oncol; 2018 Aug 08; 16(1):160. PubMed ID: 30089488
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.